Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on EPIGENOMICS AG. We currently have 4 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Q316 results and business update
11 Nov 16
Epigenomics continues to execute on the commercial front. The US is now the main market for Epi proColon, the only FDA-approved, blood-based colorectal cancer screening test. Epi proColon US sales account for c 60% of total 9M16 revenues of €0.9m, 83% up y-o-y. The remainder come from Europe and other countries. Epigenomics recently raised c €5m in a private placement. It has five convertible notes, which mature by year-end 2016 and could raise an additional €2.6m, providing funding into 2017.
Half year results published
11 Aug 16
Epigenomics has announced H116 results, which highlight the launch of Epi proColon in the US jointly with Polymedco, the largest distributor of colorectal cancer (CRC) screening tests. Epi proColon has been included in the guidelines of the US Preventive Services Task Force (USPSTF), which underscores the potential of the test as a valid screening method for CRC and recognises the need for additional screening options. The test is also now commercially available through LabCorp’s website. The company expects available cash to last into 2017.
Epi proColon gets FDA fillip
13 Jan 16
In a surprise move, the FDA has reversed its request for a new behavioural study of Epigenomics’ blood-based colorectal cancer (CRC) diagnostic test, Epi proColon. US marketing clearance and launch now look likely over the coming few months. With a current cash reach to H216, a cash call may now be deferred until after a possible US approval, and the consequent increased certainty may prove beneficial to current shareholders.
New FDA demands delay US launch further
10 Nov 15
Epigenomics announced another delay to the US launch of its blood-based CRC diagnostic test Epi proColon and a moderate downgrade to its FY15 guidance. The FDA demands more evidence of increased compliance in CRC screening using Epi proColon, which is likely to necessitate a further study. With a current cash reach to H216, a cash call is likely before a possible US approval.
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results